NYU Langone Health
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.
Inclusion Criteria: 1. Must be able to understand and sign the Informed Consent Form (ICF) 2. ≥18 years of age a. Including breastfeeding and pregnant people 3. Must have one or the other of criteria a and b, or can have both: 1. Planning receipt of (in the next 30 days) or have received the mpox vaccine, and/or 2. people with recent mpox infection who are out of isolation (≥30 days after symptom onset) 4. Willingness and ability to participate in all study procedures Exclusion Criteria: 1. Known clinically significant anemia (i.e., Hb \< 10 g/dL) 2. Contraindication to phlebotom…
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.